-
BSM Squibb acquires Karuna for $14 billion to acquire potential "first in class" therapies
Bristol Myers Squibb and Karuna Therapeutics announced a final acquisition agreement, as Bristol Myers Squibb acquires potential first in class therapies from Karuna for $14 billion. According to the ... -
Baishime Squibb CAR-T therapy approved by the US FDA
On May 30th local time, Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has approved an extended indication for its CAR-T therapy, Breyanzi (lisocabtagene maraleucel; li ...